Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.

@article{AscottEvans2003AlendronatePL,
  title={Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.},
  author={Brynne H Ascott-Evans and N{\'u}ria Gua{\~n}abens and Seppo Kivinen and Bronwyn G. A. Stuckey and Clelia H Magaril and Kristel Vandormael and Beate Stych and Mary Elkins Melton},
  journal={Archives of internal medicine},
  year={2003},
  volume={163 7},
  pages={789-94}
}
BACKGROUND Many women using hormone replacement therapy (HRT) will discontinue HRT and lose its bone-protective effect. Methods to preserve bone density in these women need to be explored. This multicenter, international, randomized, blinded, 12-month study was conducted to assess the effect of alendronate sodium on bone density in women who had recently discontinued HRT. METHODS The 144 postmenopausal women included in the study were diagnosed as having low bone mineral density (BMD) and had… CONTINUE READING
21 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Differential effects of alendronate and estrogen on the rate of bone loss after discontinuation of treatment

  • SL Greenspan, N Bell, H Bone
  • J Bone Miner Res. 1999;14(suppl 1):S158
  • 1999
Highly Influential
11 Excerpts

Similar Papers

Loading similar papers…